[ad_1]
A "multi-toxin" treatment developed by an Israeli company has raised doubts about its alleged ability to completely cure cancer. The general manager of Codeveloper, Ilan Morad, said he was confident about its effects and prospects in a recent interview with Xinhua.
According to an article in the Jerusalem Post on January 28, Dan Aridor, president of Accelerated Evolution Biotechnologies Ltd. (AEBi), 18, said: "We believe that we will offer a comprehensive cancer treatment in one year."
"Our cancer treatment will be effective from the first day, last a few weeks and will have little or no side effects at a much lower cost than most other treatments on the market," and solution will be generic. and staff, "he added.
Morad told Xinhua that the new treatment called MuTaTo (multi-target toxin) could cure cancer because a combination of several cancer-targeting peptides is used against each cancer cell, while being combined with a potent peptide toxin for destruction specific to cancer cells.
At least three targeting peptides on the same structure containing a potent toxin are used, he explained about the new treatment, which he said was "sure mutations will not be affected".
Until now, anticancer drugs have failed when mutations in targeted cancer cells render them ineffective. "Our strategy is to fight cancer by combining several attacks.It's easy to get a mutation for the cancer cell, but for example, getting three mutations at the same time, simultaneously, it's hard for a cancer cell, it's is actually impossible, "said Morad.
With a small office and a laboratory, AEBi is based in Ness Ziona, a city in central Israel. Morad said the company had two researchers and the small team had not yet submitted a paper on their new anti-cancer drug to a medical publication.
They reported on the research at the Drug Discovery Innovation Program conferences and those present were "very excited about our results and our idea," he said.
"We do not want to (publish documents) before having a strong intellectual property, like patents," Morad said.
Morad said that AEBi had completed the first exploratory mouse experiments and had given good results.
"We are experimenting with our drugs on cancer cells and on small animals, mice, we are not in the clinical phase, we are not testing it on humans yet," said Morad.
Morad said he hoped the company would soon get funding and a partnership so he could begin clinical trials a year from now.
"We do not expect to have an approved drug because it can take seven to ten years," added Morad. "If we get the right budget, we can move quickly."
MuTaTo, however, is disputed by other Israeli experts.
Skeptics said it was "pretty surprising" for them to hear about such a "stupid" badertion that they would find a 100% cancer killer.
Some required scientific publications and convincing test results, or noted that it usually took years and many experiments on animals and people before a cure became commercial.
According to the scientific literature, neither the company nor its researchers have ever published any scientific article demonstrating the validity and ability of their technology to inhibit cancer, said Rotem Karni, a professor in the department. of Biochemistry and Molecular Biology of the Faculty of Hebrew University. of Medicine, in an interview with Xinhua.
"A major step in each new technology and each drug for the treatment of patients is a thorough review of the toxicity of the new drug," said Karni, while noting that the clinical steps for the approval of a drug new drug take several years, usually in three phases test its safety, toxicity and effectiveness.
So far, in the field of cancer treatment, there are no approved drugs that are peptides. A possible problem with peptides is that an immune response can be developed against the peptides and reduce the effectiveness of this treatment. "
Shlomo Lewkowicz, head of an Israeli non-governmental organization for the prevention of colorectal cancer, said that it seemed "unrealistic" to move from the mouse to the human experience, and such a promise is " premature ".
It will take a few years and will require a huge investment, and many "dream drugs" do not work as intended when they are tested on humans, he said.
[ad_2]
Source link
